Cargando…
Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire
INTRODUCTION: Dysgeusia may occur during conventional or target-therapies and affect patients adherence-to-treatment. Therefore, it should be monitored to improve clinical outcome. To date, available questionnaires on dysgeusia relate to traditional antineoplastics and do not apply to target-therapi...
Autores principales: | Camela, Elisa, Villani, Alessia, Ocampo Garza, Sonia Sofia, Costa, Claudia, Fabbrocini, Gabriella, Megna, Matteo, Potestio, Luca, Ruggiero, Angelo, Scalvenzi, Massimiliano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mattioli 1885
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412060/ https://www.ncbi.nlm.nih.gov/pubmed/37557166 http://dx.doi.org/10.5826/dpc.1303a177 |
Ejemplares similares
-
Genetic and Epigenetic Regulation of the Smoothened Gene (SMO) in Cancer Cells
por: Lou, Hong, et al.
Publicado: (2020) -
Case Report: Prenatal Diagnosis of Postaxial Polydactyly With Bi-Allelic Variants in Smoothened (SMO)
por: Fan, Lihong, et al.
Publicado: (2022) -
Adalimumab biosimilar in a pediatric patient: Clinical and in vivo reflectance confocal microscopy evaluation
por: Megna, Matteo, et al.
Publicado: (2022) -
New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma
por: Villani, Alessia, et al.
Publicado: (2022) -
A Case of Adult-onset Facial Cutaneous Mastocytoma: Clinical and Dermoscopic Findings
por: Megna, Matteo, et al.
Publicado: (2022)